Article Per Year (5 Year)
p-Index From 2021 - 2026
0.92
P-Index
This Author published in this journals
All Journal e-CliniC Medical Scope Journal (MSJ) Jurnal Sehat Indonesia (JUSINDO)
Saleh, Denny
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Veterinary

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : e-CliniC

 1 
Small Lymphocytic Lymphoma Presenting as Breast Mass: A Rare Case Report Manginstar, Christian; Merung, Marselus A.; Saleh, Denny; Merung, Marcella
e-CliniC Vol. 12 No. 2 (2024): e-CliniC
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35790/ecl.v12i2.46852

Abstract

Abstract: Primary breast lymphoma is rare and it accounts for around 0.5% of malignant breast neoplasms. Small lymphocytic lymphoma (SLL) is a subtype of non-Hodgkin lymphoma originating from a B-cell lineage. This report presents a case of primary SLL of the breast with lung metastasis that had excellent clinical response. We reported a 67-year-old female complained a right breast mass that suddenly appeared after she got massage on her right left arm. The mass was swollen and painless with no systemic complications. The specimen was submitted to histopathology department and it revealed small diffuse lymphocytic lymphoma. Chest X-ray showed a lung metastasis. The patient was then treated with CHOP regimens (Cyclophosphamid, Doxorubicin, Vincristin, and Prednison) and the clinical result was excellent. The side effects of the medication were minimal. In conclusion, primary breast lymphocytic lymphoma is rare and this case highlights the differential diagnosis for a painless breast mass. The treatment must be individualized and multimodal, with chemotherapy being the most accepted treatment. Keywords: breast lymphoma; breast mass; malignancy
Neoadjuvant Lenvatinib in Advanced Unresectable Thyroid Carcinoma: Case Series and Literature Review Albert, Albert; Manginstar, Christian O.; Saleh, Denny; Merung, Marselus A.
e-CliniC Vol. 13 No. 1 (2025): e-CliniC
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35790/ecl.v13i1.58793

Abstract

Abstract: Lenvatinib, a tyrosine kinase inhibitor (TKI), has shown potential as a neoadjuvant therapy for inoperable thyroid cancer (TC). In this case series, we present three patients with unresectable thyroid tumors who responded favorably to lenvatinib treatment. A 60-year-old male with papillary thyroid cancer (PTC) experienced a 60% tumor volume reduction after five months of therapy. A 61-year-old male with medullary thyroid cancer (MTC) saw a 99% reduction after four months of lenvatinib and decrease of serum calcitonin and no residual disease six months after surgery. Lastly, a 67-year-old female with anaplastic thyroid cancer (ATC) showed a 70% tumor reduction and significant symptomatic relief. These cases highlight lenvatinib’s efficacy in reducing tumor size and stabilizing disease, improving surgical outcomes in patients initially deemed inoperable due to locally advanced tumors. Lenvatinib’s antitumor effects, driven by its antiangiogenic properties, suggest its potential as a valuable neoadjuvant treatment option in advanced thyroid cancer. Keywords: thyroid carcinoma; lenvatinib; case series
Co-Authors Adrian Tangkilisan, Adrian Albert Albert Candy, Candy Eko Prasetyo Gufi George Stefanus, Gufi George Harsali F. Lampus Manginstar, Christian Manginstar, Christian O. Marselus A. Merung, Marselus A. Merung, Marcella Sukanto, Wega Suryoprabowo, Vincent Tamburian, Christha